Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:AGN
- CUSIP: 01849010
- Web: www.allergan.com
Capitalization:- Market Cap: $86.03 billion
- Outstanding Shares: 335,867,000
Average Prices:- 50 Day Moving Avg: $242.61
- 200 Day Moving Avg: $235.97
- 52 Week Range: $184.50 - $261.27
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 14.29
- P/E Growth: 1.19
Sales & Book Value:- Annual Revenue: $14.74 billion
- Price / Sales: 5.84
- Book Value: $209.35 per share
- Price / Book: 1.22
Dividend:- Annual Dividend: $2.80
- Dividend Yield: 1.1%
Profitability:- EBIDTA: $5.8 billion
- Net Margins: 82.42%
- Return on Equity: 7.29%
- Return on Assets: 4.08%
Debt:- Debt-to-Equity Ratio: 0.37%
- Current Ratio: 1.32%
- Quick Ratio: 1.23%
Misc:- Average Volume: 2.22 million shs.
- Beta: 1.16
- Short Ratio: 2.45
Frequently Asked Questions for Allergan plc (NYSE:AGN)
What is Allergan plc's stock symbol?
Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan plc pay dividends? What is the dividend yield for Allergan plc?
Allergan plc announced a quarterly dividend on Friday, May 5th. Stockholders of record on Thursday, May 18th will be given a dividend of $0.70 per share on Thursday, June 15th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date of this dividend is Tuesday, May 16th. View Allergan plc's Dividend History.
How were Allergan plc's earnings last quarter?
Allergan plc (NYSE:AGN) posted its earnings results on Tuesday, May, 9th. The company reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.32 by $0.03. The firm had revenue of $3.57 billion for the quarter, compared to the consensus estimate of $3.53 billion. Allergan plc had a net margin of 82.42% and a return on equity of 7.29%. Allergan plc's revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.04 EPS. View Allergan plc's Earnings History.
When will Allergan plc make its next earnings announcement?
What guidance has Allergan plc issued on next quarter's earnings?
Allergan plc updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus estimate of $16.01.
Where is Allergan plc's stock going? Where will Allergan plc's stock price be in 2017?
17 brokerages have issued 1-year price targets for Allergan plc's shares. Their predictions range from $231.00 to $400.00. On average, they expect Allergan plc's share price to reach $275.88 in the next year. View Analyst Ratings for Allergan plc.
What are analysts saying about Allergan plc stock?
Here are some recent quotes from research analysts about Allergan plc stock:
- 1. According to Zacks Investment Research, "Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (7/11/2017)
- 2. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
Who are some of Allergan plc's key competitors?
Some companies that are related to Allergan plc include Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Medtronic PLC (MDT), AbbVie (ABBV), Bayer AG (BAYRY), Celgene Corporation (CELG), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), Thermo Fisher Scientific (TMO), Biogen (BIIB), Stryker Corporation (SYK) and Regeneron Pharmaceuticals (REGN).
Who owns Allergan plc stock?
Allergan plc's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.22%), Strs Ohio (0.20%), Factory Mutual Insurance Co. (0.15%), APG Asset Management N.V. (0.14%), Swedbank (0.10%) and Confluence Investment Management LLC (0.09%). Company insiders that own Allergan plc stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan plc.
Who sold Allergan plc stock? Who is selling Allergan plc stock?
Allergan plc's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Jag Capital Management LLC, Swedbank, Strs Ohio, OLD National Bancorp IN, Meag Munich Ergo Kapitalanlagegesellschaft MBH, FineMark National Bank & Trust and Armstrong Shaw Associates Inc. CT. Company insiders that have sold Allergan plc stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan plc.
Who bought Allergan plc stock? Who is buying Allergan plc stock?
Allergan plc's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sit Investment Associates Inc., Aviance Capital Partners LLC, Mn Services Vermogensbeheer B.V., Intermede Investment Partners Ltd, Confluence Investment Management LLC, Pennsylvania Trust Co and AMI Asset Management Corp. Company insiders that have bought Allergan plc stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro. View Insider Buying and Selling for Allergan plc.
How do I buy Allergan plc stock?
Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan plc's stock price today?
One share of Allergan plc stock can currently be purchased for approximately $256.15.
MarketBeat Community Rating for Allergan plc (NYSE AGN)MarketBeat's community ratings are surveys of what our community members think about Allergan plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Allergan plc (NYSE:AGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 12 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.71) |
| Consensus Price Target: | $275.88 (7.70% upside) |
Analysts' Ratings History for Allergan plc (NYSE:AGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/20/2017 | Credit Suisse Group | Reiterated Rating | Outperform | $274.00 -> $286.00 | Medium |  |
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $265.00 -> $273.00 | Medium | |
| 7/16/2017 | Royal Bank Of Canada | Set Price Target | Buy | $284.00 | Low | |
| 7/14/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $231.00 | Low | |
| 6/16/2017 | Cantor Fitzgerald | Initiated Coverage | Neutral -> Neutral | $231.00 | Low | |
| 6/9/2017 | Mizuho | Lower Price Target | Buy -> Buy | $275.00 -> $267.00 | Medium | |
| 6/8/2017 | Cowen and Company | Set Price Target | Buy | $400.00 | Medium | |
| 5/25/2017 | Sanford C. Bernstein | Reiterated Rating | Outperform | | Low | |
| 5/10/2017 | Goldman Sachs Group, Inc. (The) | Downgrade | Buy -> Neutral | $262.00 | High | |
| 4/24/2017 | Citigroup Inc. | Boost Price Target | Buy | $261.00 | Low | |
| 2/9/2017 | Leerink Swann | Boost Price Target | Buy | $280.00 | N/A | |
| 12/23/2016 | Bank of America Corporation | Reiterated Rating | Buy | $280.00 | N/A | |
| 12/6/2016 | Argus | Reiterated Rating | Buy | $340.00 -> $260.00 | N/A | |
| 12/5/2016 | J P Morgan Chase & Co | Set Price Target | Buy | $300.00 | N/A | |
| 11/21/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
| 11/3/2016 | Morgan Stanley | Lower Price Target | Overweight | $300.00 -> $274.00 | N/A | |
| 10/31/2016 | Barclays PLC | Reiterated Rating | Equal Weight | $250.00 | N/A | |
| 6/10/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 4/18/2016 | Guggenheim | Initiated Coverage | Neutral | | N/A | |
| 4/12/2016 | S&P Equity Research | Reiterated Rating | Buy | | N/A | |
| 4/7/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $317.00 -> $275.00 | N/A | |
| 4/7/2016 | Canaccord Genuity | Reiterated Rating | Buy | | N/A | |
| 4/7/2016 | Susquehanna Bancshares Inc | Downgrade | Positive -> Neutral | $345.00 -> $275.00 | N/A | |
| 4/5/2016 | Nomura | Reiterated Rating | Buy | $350.00 -> $330.00 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Allergan plc (NYSE:AGN)Earnings History by Quarter for Allergan plc (NYSE AGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | | $3.93 | | | | | N/A | |
| 5/9/2017 | Q1 2017 | $3.32 | $3.35 | $3.53 billion | $3.57 billion | View | Listen | |
| 2/8/2017 | Q416 | $3.76 | $3.90 | $3.77 billion | $3.86 billion | View | Listen | |
| 11/2/2016 | Q316 | $3.57 | $3.32 | $3.73 billion | $3.62 billion | View | Listen | |
| 8/8/2016 | Q216 | $3.34 | $3.35 | $4.10 billion | $3.68 billion | View | Listen | |
| 5/10/2016 | Q116 | $3.03 | $3.04 | $3.97 billion | $3.80 billion | View | Listen | |
| 2/22/2016 | Q415 | $3.36 | $3.41 | $4.20 billion | $4.20 billion | View | Listen | |
| 11/4/2015 | Q315 | $3.20 | $3.48 | $5.71 billion | $4.10 billion | View | N/A | |
| 8/6/2015 | Q215 | $4.41 | $4.41 | $5.71 billion | $5.76 billion | View | N/A | |
| 11/5/2014 | Q414 | $1.83 | $2.17 | $1.90 billion | $1.91 billion | View | N/A | |
| 8/5/2014 | Q314 | $1.76 | $1.78 | $1.78 billion | $1.79 billion | View | Listen | |
| 7/21/2014 | Q214 | $1.44 | $1.51 | $1.77 billion | $1.83 billion | View | N/A | |
| 4/30/2014 | Q114 | $1.13 | $1.18 | $1.60 billion | $1.65 billion | View | N/A | |
| 2/4/2014 | Q413 | $1.34 | $1.12 | $1.65 million | $1.66 million | View | N/A | |
| 10/29/2013 | Q313 | $1.20 | $1.23 | $1.53 billion | $1.23 billion | View | Listen | |
| 7/31/2013 | Q2 2013 | $1.20 | $1.22 | $1.56 billion | $1.60 billion | View | N/A | |
| 5/1/2013 | Q1 2013 | $0.96 | $0.98 | $1.44 billion | $1.46 billion | View | N/A | |
| 2/5/2013 | Q4 2012 | $1.20 | $1.15 | $1.51 million | $1.48 million | View | N/A | |
| 10/30/2012 | Q312 | $1.04 | $1.06 | $1.43 billion | $1.39 billion | View | N/A | |
| 8/1/2012 | | $1.06 | $1.07 | | | View | N/A | |
| 5/2/2012 | | $0.87 | $0.86 | | | View | N/A | |
| 2/2/2012 | | $1.00 | $1.00 | | | View | N/A | |
| 10/26/2011 | | $0.90 | $0.92 | | | View | N/A | |
| 8/3/2011 | | $0.95 | $0.96 | | | View | N/A | |
| 5/4/2011 | | $0.74 | $0.77 | | | View | N/A | |
| 2/2/2011 | | $0.89 | $0.88 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Allergan plc (NYSE:AGN)2017 EPS Consensus Estimate: $16.20
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $3.33 | $3.55 | $3.44 |
| Q2 2017 | 2 | $4.00 | $4.07 | $4.04 |
| Q3 2017 | 2 | $4.09 | $4.16 | $4.13 |
| Q4 2017 | 2 | $4.52 | $4.67 | $4.60 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Allergan plc (NYSE:AGN)| Most Recent Dividend: | 6/15/2017 |
| Annual Dividend: | $2.80 |
| Dividend Yield: | 1.09% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 9.63% (Trailing 12 Months of Earnings)
17.41% (Based on This Year's Estimates)
15.62% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Allergan plc (NYSE AGN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/5/2017 | quarterly | $0.70 | 0.01% | 5/16/2017 | 5/18/2017 | 6/15/2017 |
| 11/2/2016 | quarterly | $0.70 | | 2/24/2017 | 2/28/2017 | 3/28/2017 |
| 2/4/2015 | quarterly | $0.05 | 0.09% | 2/5/2015 | 2/9/2015 | 3/20/2015 |
| 10/27/2014 | quarterly | $0.05 | | | 11/20/2014 | 12/11/2014 |
| 7/28/2014 | quarterly | $0.05 | 0.12% | 8/13/2014 | 8/15/2014 | 9/5/2014 |
| 5/7/2014 | quarterly | $0.05 | 0.12% | 5/21/2014 | 5/23/2014 | 6/13/2014 |
| 2/5/2014 | quarterly | $0.05 | 0.17% | 2/26/2014 | 2/28/2014 | 3/21/2014 |
| 10/30/2013 | quarterly | $0.05 | 0.22% | 11/18/2013 | 11/20/2013 | 12/11/2013 |
| 7/31/2013 | quarterly | $0.05 | 0.22% | 8/20/2013 | 8/22/2013 | 9/12/2013 |
| 5/2/2013 | quarterly | $0.05 | 0.2% | 5/21/2013 | 5/23/2013 | 6/13/2013 |
| 2/6/2013 | quarterly | $0.05 | 0.18% | 2/26/2013 | 2/28/2013 | 3/21/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Allergan plc (NYSE:AGN)Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 84.68%
Insider Trades by Quarter for Allergan plc (NYSE:AGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/18/2017 | Nesli Basgoz | Director | Sell | 1,889 | $220.45 | $416,430.05 | |
| 3/2/2017 | Paul Bisaro | Director | Sell | 70,000 | $246.68 | $17,267,600.00 | |
| 12/8/2016 | Nesli Basgoz | Director | Sell | 500 | $188.72 | $94,360.00 | |
| 11/21/2016 | Brent L. Saunders | CEO | Buy | 5,250 | $189.13 | $992,932.50 | |
| 11/11/2016 | Maria Teresa Hilado | CFO | Buy | 1,422 | $210.64 | $299,530.08 | |
| 6/2/2016 | Maria Teresa Hilado | CFO | Buy | 661 | $241.57 | $159,677.77 | |
| 5/11/2016 | Nesli Basgoz | Director | Sell | 459 | $225.10 | $103,320.90 | |
| 12/7/2015 | Nesli Basgoz | Director | Sell | 2,300 | $312.96 | $719,808.00 | |
| 8/24/2015 | Paul Bisaro | Chairman | Buy | 1,000 | $297.42 | $297,420.00 | |
| 8/21/2015 | Brent L Saunders | CEO | Buy | 1,000 | $301.94 | $301,940.00 | |
| 4/22/2014 | Scott Sherman | EVP | Sell | 14,500 | $155.82 | $2,259,390.00 | |
| 2/21/2014 | Louis Lavigne, Jr. | Director | Sell | 5,400 | $125.79 | $679,266.00 | |
| 2/19/2014 | Dawn Hudson | Director | Sell | 4,200 | $126.35 | $530,670.00 | |
| 2/19/2014 | Jeffrey Edwards | CFO | Sell | 38,900 | $126.39 | $4,916,571.00 | |
| 2/19/2014 | Raymond Diradoorian | EVP | Sell | 23,000 | $126.66 | $2,913,180.00 | |
| 2/18/2014 | Scott Sherman | EVP | Sell | 5,001 | $125.74 | $628,825.74 | |
| 1/14/2014 | Scott Whitcup | VP | Sell | 42,000 | $117.80 | $4,947,600.00 | |
| 12/27/2013 | Julian Gangolli | VP | Sell | 52,500 | $110.05 | $5,777,625.00 | |
| 12/20/2013 | Scott Whitcup | VP | Sell | 33,000 | $108.80 | $3,590,400.00 | |
| 10/15/2013 | Trevor Jones | Director | Sell | 2,000 | $90.14 | $180,280.00 | |
| 9/16/2013 | Trevor Jones | Director | Sell | 2,000 | $89.78 | $179,560.00 | |
| 8/15/2013 | Trevor Jones | Director | Sell | 2,000 | $89.89 | $179,780.00 | |
| 8/6/2013 | Jeffrey Edwards | CFO | Sell | 69,200 | $91.17 | $6,308,964.00 | |
| 7/15/2013 | Trevor M Jones | Director | Sell | 2,000 | $91.15 | $182,300.00 | |
| 6/17/2013 | Trevor M Jones | Director | Sell | 2,000 | $101.25 | $202,500.00 | |
| 5/15/2013 | Trevor M Jones | Director | Sell | 2,000 | $103.40 | $206,800.00 | |
| 5/9/2013 | Jeffrey L Edwards | CFO | Sell | 84,000 | $103.49 | $8,693,160.00 | |
| 11/26/2012 | Trevor M Jones | Director | Sell | 2,500 | $91.30 | $228,250.00 | |
| 10/5/2012 | David E I Pyott | CEO | Sell | 616,300 | $93.73 | $57,765,799.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Allergan plc (NYSE:AGN)
Latest Headlines for Allergan plc (NYSE:AGN)
| Source: |
|
| Date | Headline |
|---|
 | Notable Tuesday Option Activity: MU, WMT, AGN - Nasdaq.com - Nasdaq
www.nasdaq.com - July 25 at 3:29 PM |
 | Head to Head Review: Allergan PLC. (NYSE:AGN) vs. Sophiris Bio (SPHS)
www.americanbankingnews.com - July 24 at 10:18 PM |
| SOL Capital Management CO Buys PIMCO Enhanced Short Maturity Active Exchange-Trad, Vanguard ...
www.nasdaq.com - July 22 at 8:36 PM |
| Allergan PLC. (NYSE:AGN) Earns Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - July 20 at 9:06 AM |
| Equities Analysts Offer Predictions for Allergan PLC.'s Q2 2017 Earnings (AGN)
www.americanbankingnews.com - July 20 at 8:16 AM |
 | Technical Reports on Generic Drugs Equities -- Allergan, Ironwood Pharma, Medicines Co., and Catalent - PR Newswire (press release)
www.prnewswire.com - July 19 at 4:35 PM |
 | Allergan (AGN) Appoints Joseph Boccuzi to Board - StreetInsider.com
www.streetinsider.com - July 19 at 4:35 PM |
| Q4 2017 EPS Estimates for Allergan PLC. Raised by Analyst (NYSE:AGN)
www.americanbankingnews.com - July 19 at 12:38 PM |
| Head-To-Head Analysis: NephroGenex (NRX) vs. Allergan PLC. (AGN)
www.americanbankingnews.com - July 19 at 8:51 AM |
| Noteworthy ETF Inflows: PFF, AGN, HSBC, DB - Nasdaq
www.nasdaq.com - July 18 at 4:45 PM |
 | How Allergan’s US Specialized Therapeutics Segment Performed
finance.yahoo.com - July 18 at 2:04 AM |
| Allergan PLC. (NYSE:AGN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 12:48 AM |
| Allergan PLC. (NYSE:AGN) Stock Rating Reaffirmed by Deutsche Bank AG
www.americanbankingnews.com - July 17 at 9:02 PM |
| Noteworthy Monday Option Activity: VHC, AGN, BIIB - Nasdaq
www.nasdaq.com - July 17 at 3:58 PM |
| Inside Allergan’s International Business
finance.yahoo.com - July 17 at 3:58 PM |
| Valeant Unloads Yet Another Unit
finance.yahoo.com - July 17 at 3:58 PM |
| Allergan PLC. (AGN) Stock Rating Reaffirmed by Royal Bank Of Canada
www.americanbankingnews.com - July 16 at 7:32 AM |
| Allergan PLC. (NYSE:AGN) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - July 15 at 10:16 AM |
| What Allergan’s Valuation as of July 13 Tells Us
finance.yahoo.com - July 14 at 5:25 PM |
| Understanding Allergan’s Revenue Stream for 2017
finance.yahoo.com - July 14 at 5:25 PM |
| Behind Allergan’s Business Segments and Revenues
finance.yahoo.com - July 14 at 5:25 PM |
| Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
finance.yahoo.com - July 13 at 4:19 PM |
| Allergan Lends Support to Broaden Uterine Fibroid Awareness Month
finance.yahoo.com - July 13 at 4:19 PM |
 | Credit Suisse likes Allergan, sees 12% upside - Seeking Alpha
seekingalpha.com - July 12 at 4:02 PM |
| Zacks: Analysts Anticipate Allergan PLC. (NYSE:AGN) Will Announce Quarterly Sales of $3.96 Billion
www.americanbankingnews.com - July 12 at 9:51 AM |
| Allergan PLC. (AGN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:14 PM |
 | Allergan Reports Positive New Data on Irritable Bowl Drug
www.zacks.com - July 11 at 4:47 PM |
| A Look at Allergan’s Performance in 2Q17
finance.yahoo.com - July 11 at 4:47 PM |
| Zacks: Brokerages Expect Allergan PLC. (NYSE:AGN) to Post $3.98 EPS
www.americanbankingnews.com - July 10 at 6:18 PM |
| Allergan (AGN) Says New Data Reinforces Effectiveness of Viberzi ... - StreetInsider.com
www.streetinsider.com - July 10 at 3:19 PM |
| Too Early To Roll The Dice With Allergan - Seeking Alpha
seekingalpha.com - July 10 at 3:19 PM |
 | UK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents - TheStreet.com
www.thestreet.com - July 7 at 5:34 PM |
| Allergan, Celgene Offer Solid Biotech Value
finance.yahoo.com - July 7 at 5:33 PM |
| 10 Attractively Valued Stocks With Competitive Edge
finance.yahoo.com - July 5 at 9:10 PM |
| Allergan PLC. (AGN) to Post FY2017 Earnings of $16.07 Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - July 3 at 9:04 AM |
| EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Allergan, Inc.
finance.yahoo.com - July 1 at 1:52 AM |
| [$$] Oklahoma Sues Opioid Painkiller Makers
finance.yahoo.com - June 30 at 3:43 PM |
| Securities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Allergan, Inc. During the Period February 25, 2014 Through April 21, 2014, Inclusive
finance.yahoo.com - June 30 at 3:43 PM |
| Oklahoma sues opioid drugmakers; New Hampshire presses epidemic probe
finance.yahoo.com - June 30 at 3:43 PM |
| Critical Review: Allergan PLC. (AGN) and NephroGenex (NRX)
www.americanbankingnews.com - June 30 at 9:09 AM |
| Sarepta appoints former Allergan executive Douglas Ingram as CEO - Nasdaq
www.nasdaq.com - June 29 at 1:53 AM |
| Notable ETF Inflow Detected - VHT, GILD, LLY, AGN
www.nasdaq.com - June 28 at 3:50 PM |
| Allergan Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest Innovation in the REFRESH® Portfolio
finance.yahoo.com - June 27 at 3:29 PM |
| Bill Ackman's Big Triumph Becomes His Big Problem
finance.yahoo.com - June 27 at 3:29 PM |
| Valeant: Out of the Frying Pan, Into the Fire
finance.yahoo.com - June 27 at 3:29 PM |
| Allergan PLC. (AGN) Lifted to Buy at BidaskClub
www.americanbankingnews.com - June 24 at 9:06 PM |
| Stock Traders Purchase High Volume of Allergan PLC. Put Options (AGN)
www.americanbankingnews.com - June 23 at 12:37 PM |
| Investors Purchase Large Volume of Allergan PLC. Call Options (AGN)
www.americanbankingnews.com - June 22 at 12:32 PM |
| Missouri sues opioid manufacturers, joining two other U.S. states
www.nasdaq.com - June 21 at 4:10 PM |
| Todd Hagopian's Top 2 Mental Health Biotech Stocks
finance.yahoo.com - June 21 at 4:10 PM |
Allergan plc (AGN) Chart for Thursday, July, 27, 2017
